We are live on
!
Find out more
YIH
Y-Intercept (HK) Portfolio holdings
AUM
$5.05B
1-Year Est. Return
17.89%
This Fund
S&P 500
This Quarter
Est. Return
+8.14%
1 Year Est. Return
+17.89%
3 Year Est. Return
+34.37%
5 Year Est. Return
+20.59%
10 Year Est. Return
–
AUM
$4.09B
AUM Growth
+$2.61B
(+177%)
Cap. Flow
+$2.46B
Cap. Flow
% of AUM
60.1%
Top 10 Holdings %
Top 10 Hldgs %
6.33%
Holding
2,105
New
963
Increased
487
Reduced
137
Closed
518
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$37.8M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$35.1M |
| 3 |
T-Mobile US
TMUS
|
+$30.4M |
| 4 |
Nu Holdings
NU
|
+$27.8M |
| 5 |
Consolidated Edison
ED
|
+$26.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arista Networks
ANET
|
+$17M |
| 2 |
Marvell Technology
MRVL
|
+$16.2M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$16.1M |
| 4 |
ServiceNow
NOW
|
+$13.3M |
| 5 |
Walmart Inc
WMT
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.87% |
| 2 | Industrials | 14.69% |
| 3 | Financials | 14.36% |
| 4 | Healthcare | 12.68% |
| 5 | Consumer Discretionary | 12.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1526
TScan Therapeutics
TCRX
$48.5M
| $111K | ﹤0.01% |
+76,660
| New | +$111K |
|
1527
Lumen
LUMN
$6.43B
| $110K | ﹤0.01% |
25,000
+12,488
| +100% | +$48.4K |
|
|
DCH
1528
Dauch Corp
DCH
$1.31B
| $109K | ﹤0.01% |
+26,816
| New | +$108K |
|
1529
indie Semiconductor
INDI
$636M
| $109K | ﹤0.01% |
+30,719
| New | +$77.3K |
|
|
TPIC
1530
DELISTED
TPI Composites
TPIC
| $106K | ﹤0.01% |
+122,884
| New | +$125K |
|
1531
Coty
COTY
$2.4B
| $105K | ﹤0.01% |
22,630
+12,433
| +122% | +$61.6K |
|
|
MFA
1532
MFA Financial
MFA
$932M
| $105K | ﹤0.01% |
11,100
-28,307
| -72% | -$267K |
|
1533
Lifezone Metals
LZM
$275M
| $105K | ﹤0.01% |
+25,420
| New | +$94.7K |
|
1534
Purple Innovation
PRPL
$34.5M
| $99.4K | ﹤0.01% |
+5,450
| New | +$100K |
|
1535
Verrica Pharmaceuticals
VRCA
$89M
| $99.1K | ﹤0.01% |
+18,696
| New | +$101K |
|
1536
RLX Technology
RLX
$2.37B
| $98.9K | ﹤0.01% |
+44,757
| New | +$87.5K |
|
1537
Shattuck Labs
STTK
$646M
| $97.5K | ﹤0.01% |
+123,172
| New | +$119K |
|
1538
Ring Energy
REI
$307M
| $96.6K | ﹤0.01% |
+121,716
| New | +$103K |
|
1539
Werewolf Therapeutics
HOWL
$22.4M
| $92K | ﹤0.01% |
+84,421
| New | +$86.9K |
|
1540
Actinium Pharmaceuticals
ATNM
$26.3M
| $90.9K | ﹤0.01% |
+64,909
| New | +$97.1K |
|
1541
GoPro
GPRO
$120M
| $89.9K | ﹤0.01% |
+118,730
| New | +$77.2K |
|
1542
Veru
VERU
$35.5M
| $89.6K | ﹤0.01% |
+15,403
| New | +$86.5K |
|
1543
Inovio Pharmaceuticals
INO
$85.6M
| $85.8K | ﹤0.01% |
+42,171
| New | +$80.8K |
|
1544
Alto Neuroscience
ANRO
$1.04B
| $84.9K | ﹤0.01% |
+38,597
| New | +$91.8K |
|
1545
Cullinan Oncology
CGEM
$1.06B
| $83.8K | ﹤0.01% |
+11,129
| New | +$89.4K |
|
1546
Telomir Pharmaceuticals
TELO
$83.2M
| $80.5K | ﹤0.01% |
+64,423
| New | +$149K |
|
1547
Chegg
CHGG
$116M
| $80.4K | ﹤0.01% |
+66,438
| New | +$61.4K |
|
1548
Horizon Technology Finance
HRZN
$294M
| $77.3K | ﹤0.01% |
+10,731
| New | +$83.6K |
|
1549
Stagwell
STGW
$2B
| $75.6K | ﹤0.01% |
+16,805
| New | +$84.5K |
|
1550
Solarmax Technology
SMXT
$20.5M
| $75.2K | ﹤0.01% |
+69,033
| New | +$78.3K |
|
Similar funds
HSA
O
LFG
JIM
CTC
NL
BPWM
VT
Y-Intercept (HK)'s Q2 2025 Portfolio in Review
As of Q2 2025, Y-Intercept (HK) held 2,105 positions worth $4.09B, up 177% from $1.48B the previous quarter. Its ten largest holdings account for 6.3% of the portfolio.
Y-Intercept (HK) deployed $2.46B of net new capital in Q2 2025, opening 963 new positions and adding to 487 existing holdings. Its largest new stake was Nu Holdings: 2,319,643 shares worth $31.8M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 19% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Novo Nordisk, an estimated $16.1M trimmed.
- Y-Intercept (HK)'s largest Q2 2025 buy was Nu Holdings: 2,319,643 shares worth $31.8M.
- Y-Intercept (HK) added most to UnitedHealth in Q2 2025, an estimated $37.8M increase.
- Y-Intercept (HK)'s biggest Q2 2025 reduction was Novo Nordisk, cutting an estimated $16.1M.
- Y-Intercept (HK) fully exited Arista Networks in Q2 2025, selling an estimated $17M.
- Y-Intercept (HK)'s ten largest holdings make up 6.3% of its $4.09B portfolio in Q2 2025.
- Y-Intercept (HK) opened 963 new positions and closed 518 in Q2 2025.
- Y-Intercept (HK)'s portfolio value rose 177% quarter-over-quarter to $4.09B.
Based on Y-Intercept (HK)'s 13F filing for Q2 2025, filed 1 Aug 2025.